Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics

ACS Chemical Biology

Volumn 9, Issue 10, 2014, Pages 2334-2346

  Cho, Hyekyung P ^a   Garcia Barrantes, Pedro M ^a   Brogan, John T ^a   Hopkins, Corey R ^a,b   Niswender, Colleen M ^a   Rodriguez, Alice L ^a   Venable, Daryl F ^a   Morrison, Ryan D ^a   Bubser, Michael ^a   Daniels, J Scott ^a   Jones, Carrie K ^a   Conn, P Jeffrey ^a   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIHYDROXYPHENYLGLYCINE; GLUTAMATE RECEPTOR AGONIST; METABOTROPIC RECEPTOR 1; CALCIUM; GLUTAMIC ACID; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; MOLECULAR LIBRARY;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CALCIUM MOBILIZATION ASSAY; CALCIUM SIGNALING; CELL LINE; CELL MEMBRANE; CELL SURFACE; CHEMICAL MODIFICATION; CHEMICAL MODULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENOTYPE; GRM1 GENE; HUMAN; HUMAN CELL; HYDROLYSIS; LOSS OF FUNCTION MUTATION; MALE; MOLECULAR BIOLOGY; MOLECULAR SWITCH; NEGATIVE ALLOSTERIC MODULATOR; NONHUMAN; PATIENT SELECTION; POSITIVE ALLOSTERIC MODULATOR; RAT; SCHIZOPHRENIA; WESTERN BLOTTING; WILD TYPE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HEK293 CELL LINE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LOCOMOTION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MOLECULAR LIBRARY; MUTATION; PHARMACOLOGY; SPRAGUE DAWLEY RAT;

ALLOSTERIC REGULATION; ANIMALS; CALCIUM; CHROMATOGRAPHY, LIQUID; GENOME-WIDE ASSOCIATION STUDY; GLUTAMIC ACID; HEK293 CELLS; HUMANS; LOCOMOTION; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MUTATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SMALL MOLECULE LIBRARIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84908154937     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500560h     Document Type: Article

References (41)

1. Weinberger, D. R., and Harrison, P. J., Eds. (2011) Schizophrenia, 3rd Ed. Wiley-Blackwell Publishing, Ltd., Oxford, U.K.
2. Carlsson, A., and Lindquist, M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normethanephrine in mouse brain. Acta Pharmacol. Toxicol. 20, 140-144.
3. Andreasen, N. C. (2000) Schizophrenia: The fundamental questions. Brain Res. Rev. 31, 106-112.
4. Karayiorgou, M. (2001) Genetic aspects of schizophrenia. Clin. Neurosci. Res. 1, 158-163.
5. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
6. Seeman, P., and Lee, T. (1975) Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219.
7. Olney, J. W., Newcomer, J. W., and Farber, N. B. (1999) NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33, 523-533.
8. Lindsley, C. W., Shipe, W. D., Wolkenberg, S. E., Theberge, C. R., Williams, D. L., Jr., Sur, C., and Kinney, G. G. (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 8, 771-784.
9. Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., and Volkmann, R. A. (2013) Allosteric modulation for the treatment of schizophrenia: Targeting glutamatergic networks. Curr. Top. Med. Chem. 13, 26-54.
10. Moghaddam, B., and Javitt, D. (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implications for treatment. Neuropsychopharmacology Rev. 37, 4-15.
11. Conn, P. J., Tamminga, C., Schoepp, D. D., and Lindsley, C. (2008) Schizophrenia: Moving beyond monoamine antagonists. Mol. Intervent. 8, 99-105.
12. Yao, W., Spealman, R., and Zhang, J. (2006) Dopaminergic signaling in dendritic spines. Biochem. Pharmacol. 75, 2055-2069.
13. Zhang, J., Vinuela, A., Neely, M. H., Hallett, P. J., Grant, S. G. N., Miller, G. M., Isacson, O., Caron, M. G., and Yao, W.-D. (2007) Inhibition of the dopamine D1 receptor signaling by PSD-95?. J. Biol. Chem. 282, 15778-15789.
14. Soares, D. C., Carlyle, B. C., Bradshaw, N. J., and Porteus, D. L. (2011) DISC1: Structure, function, and therapeutic potential for mental illness. ACS Chem. Neurosci. 2, 609-632.
15. Li, T., Shan, P. C., Vallada, H., Xie, T., Murray, R. M., and Collier, D. A. (1996) Preferential transmission of the high activity allele of COMT in schizophrenia. Pyschiatr. Genet. 6, 131-134.
16. Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., Stray, S. M., Rippey, C. F., Roccanova, P., Makarov, V., Lakshmi, B., Findling, R. L., Sikich, L., Stromberg, T., Merriman, B., Gogtay, N., Butler, P., Eckstrand, K., Noory, L., Gochman, P., Long, R., Chen, Z., Davis, S., Baker, C., Eichler, E. E., Meltzer, P. S., Nelson, S. F., Singelton, A. B., Lee, M. K., Rapoport, J. L., King, M.-C., and Sebat, J. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320, 539-543.
17. Stone, J. L., O'Donovan, M. C., Gurling, H., Kirov, G. K., Blackwood, D. H. R., Corvin, A., Craddock, N. J., Gill, M., Hultman, C. M., Lichtenstein, P., McQuillin, A., Pato, C. N., Ruderfer, D. M., Owen, M. J., St. Clair, D., Sullivan, P. F., Sklar, P., and Purcell, S. M. (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455, 237-241.
18. Stefansson, H., Rujescu, D., Cichon, S., Pietiläinen, O. P. H., Ingason, A., Steinberg, S., Fossdal, R., Sigurdsson, E., Sigmundsson, T., et al. (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455, 232-236.
19. Need, A. C., Ge, D., Weale, M. E., Maia, J., Feng, S., Heinzen, E. L., Shianna, K. V., et al. (2009) A genome-wide investigation of SNPs and CNVs in schizophrenia. PloS Genet. 5, e1000373.
20. Zeggini, E., Rayner, W., Morris, A. P., Hattersley, A. T., Walker, M., Hitman, G. A., Deloukas, P., Cardon, L. R., and McCarthy, M. I. (2005) An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data sets. Nat. Genet. 37, 1320-1322.
21. Frank, R. A. W., McRae, A. F., Pocklington, A. J., van de Lagemaat, L. N., Navarro, P., Croning, M. D. R., Komiyama, N. H., Bradley, S. J., Challiss, R. A. J., Armstrong, J. D., Finn, R. D., Malloy, M. P., MacLean, A. W., Harris, S. E., Starr, J. M., Bhaskar, S. S., Howard, E. K., Hunt, S. E., Coffey, A. J., Raganath, V., Deloukas, P., Rogers, J., Muir, W. J., Deary, I. J., Blackwood, D. H., Visscher, P. M., and Grant, S. G. N. (2011) Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS One 6, e19011.
22. Ayoub, M. A., Angelicheva, D., Vile, D., Chandler, D., Morar, B., Cavanaugh, J. A., Visscher, P. M., Jablensky, A., Pfleger, K. D. G., and Kalaydijeva, L. (2012) Deleterious GRM1 mutations in schizophrenia. PLoS One 7, e32849.
23. Stauffer, S. R. (2011) Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5). ACS Chem. Neurosci. 2, 450-470.
24. Gupta, D. S., McCullumsmith, R. E., Beneyto, M., Haraoutunian, V., Davis, K. L., et al. (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57, 123-131.
25. Volk, D. W., Eggan, S. M., and Lewis, D. A. (2010) Alteration in metabotropic glutamate receptor 1a and regulator G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 167, 1489-1498.
26. Brody, S. A., Conquet, F., and Geyer, M. A. (2003) Disruption in prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci. 18, 2261-2266.
27. Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J., and Lindsley, C. W. (2011) Molecular switches on allosteric ligands that modulate modes of pharmacology. Biochemistry 50, 2403-2410.
28. Jones, C. K., Engers, D. W., Thompson, A. D., Field, J. R., Blobaum, A. L., Lindsley, S. R., Zhou, Y., Gogliotti, R. D., Jadhav, S., Zamorano, R., Daniels, J. S., Morrison, R., Weaver, C. D., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2011) Discovery, synthesis, SAR development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)-phenylpicolinamides: Characterization of VU0195 (ML182) as a centrally active positive allosteric modulator of metabotropic glutamate receptor 4 (mGlu4) with oral efficacy in an anti-Parkinsonian animal model. J. Med. Chem. 54, 7639-7647.
29. Emery, A. C., DiRaddo, J. O., Miller, E., Hathaway, H. A., Pshenichikin, S., Takoudjou, G. R., Grajkowska, E., Yasuda, R. P., Wolfe, B. B., and Wroblewski, J. T. (2012) Ligand bias at metabotropic glutamate 1a receptors: Molecular determinants that distinguish β-arrestin-mediated from G protein-mediate signaling. Mol. Pharmacol. 82, 291-301.
30. Cho, H. P., Engers, D. W., Venable, D. F., Niswender, C. M., Lindsley, C. W., Conn, P. J., Emmitte, K. A., and Rodriguez, A. L. (2014) A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between rat and human receptors. ACS Chem. Neurosci. 5, 597-610.
31. 1). ASC Chem. Neurosci. 2, 394-401.
32. Urwyler, S. (2011) Allosteric modulation of Family C G-Protein-Coupled receptors: From molecular insights to therapeutic perspectives. Pharmacol. Rev. 63, 59-126.
33. Engers, D. W., and Lindsley, C. W. (2013) Allosteric modulation of Class C GPCRs: A novel approach for the treatment of CNS disorders. Drug Discovery Today: Technol. 10, e269-e276.
34. Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N., Malherbe, P., Vieira, E., Wichmann, J., and Kemp, J. A. (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site. Proc. Natl. Acad. Sci.U.S.A. 98, 13402-13407.
35. Vieira, E., Huwyler, J., Jolidon, S., Knoflach, F., Mutel, V., and Wichmann, J. (2005) 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl and (2H-tertazol-5-yl)-amides as potent, orally available mGlu1 enhancers. Bioorg. Med., Chem. Lett. 15, 4628-4631.
36. Vieira, E., Huwyler, J., Jolidon, S., Knoflach, F., Mutel, V., and Wichmann, J. (2009) Fluorinated 9H-Xanthene-9-carboxylic acid oxazol-2-yl amides as potent, orally available mGlu1 enhancers. Bioorg. Med., Chem. Lett. 19, 1666-1669.
37. Hemstapat, K., dePaulis, T., Chen, Y., Brady, A. E., Grover, V. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol. 70, 616-626.
38. Williams, R., Zhou, Y., Niswender, C. M., Luo, Q., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2011) Re-exploration of the PHCCC scaffold: Discovery of improved positive allosteric modulators of mGluR4. ACS Chem. Neurosci. 1, 411-419.
39. Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katrich, V., Meiler, J., Chrezov, V., Conn, P. J., and Stevens, R. C. (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound an allosteric modulator. Science 344, 58-64.
40. 3 selective and CNS penetrant negative allosteric modulator (NAM). J. Med. Chem. 56, 3713-3718.
41. Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A., Bridges, T. M., Kennedy, J. P., Bradley, S. R., Peterson, T., Baldwin, R. M., Kessler, R., Deutch, A., Lah, J. L., Levey, A. I., Lindsley, C. W., and Conn, P. J. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 28 (41), 10422-10433.